| abstract |
The invention has valuable pharmacological properties, in particular the group R 1 which binds to G protein-coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR1) and modulates its activity. Relates to compounds of the general formula I as described in This compound is a disease that can be affected by this receptor, metabolic diseases such as diabetes, more specifically type 2 diabetes mellitus, and insulin resistance, obesity, cardiovascular disease and dyslipidemia associated with the disease Suitable for the treatment and prevention of conditions including symptoms. I |